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ABSTRACT 
Anna Ruth Riley 
 
PROPOXYPHENE, NORPROPOXYPHENE, AND PROADIFEN (SKF-525A) ARE 
MECHANISM-BASED INHIBITORS OF CYP3A4, CYP3A5, AND CYP3A IN 
HUMAN LIVER MICROSOMES  
 
The purpose of this study is to determine if propoxyphene and norpropoxyphene 
are mechanism-based (irreversible) inhibitors of CYP3A, and to determine if 
propoxyphene and norpropoxyphene are reversible inhibitors of CYP3A. Mechanism-
based inhibition is a type of irreversible inhibition that results from an inhibitor or its 
metabolite binding to an enzyme during drug metabolism, which renders the enzyme 
nonfunctional. 
            Propoxyphene is an analgesic that is frequently prescribed in the United States 
and Europe. It is metabolized by CYP3A enzymes, and is an irreversible inhibitor of 
CYP3A4. The major metabolite of propoxyphene is norpropoxyphene, which has not 
been extensively studied for enzyme inhibition. Proadifen (SKF-525a) is not a marketed 
drug, but it is a known CYP inhibitor that is structurally similar to propoxyphene and 
norpropoxyphene. Propoxyphene, norpropoxyphene, and proadifen were characterized in 
these studies with CYP3A4(+b5), CYP3A5(+b5) and pooled human liver microsomes. 
Time-dependent and concentration-dependent loss of activity of CYP3A was measured 
by formation of testosterone product. Propoxyphene and norpropoxyphene exhibited the 
greatest inhibition with CYP3A in human liver microsomes, followed by CYP3A4(+b5), 
and CYP3A5(+b5). Both compounds formed metabolic-inhibitor complexes with 
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CYP3A4(+b5) and CYP3A5(+b5), but not with human liver microsomes. Proadifen was 
a more potent inhibitor of CYP3A4(+b5) than of human liver microsomes and 
CYP3A5(+b5). The KI values of propoxyphene and CYP3A4(+b5) and human liver 
microsomes fall within the range of reported therapeutic blood levels of propoxyphene, 
with reversible inhibition constants (Ki values) above therapeutic blood concentrations 
for propoxyphene and norpropoxyphene. The KI values of norpropoxyphene and 
CYP3A4(+b5) and human liver microsomes are higher than most reported blood levels, 
except for blood levels after repeated dosing of propoxyphene at high concentrations. The 
predicted change in the area under the plasma concentration versus time curve of an 
orally administered CYP3A substrate with propoxyphene (AUC'po/AUCpo) was calculated 
for common CYP3A substrates. The AUC'po/AUCpo ratios are four to twenty-five times 
higher with co-administration of propoxyphene based on in vitro kinetic parameters. 
Propoxyphene and norpropoxyphene may cause adverse events when chronically 
administered at high doses and/or when co-administered with other CYP3A substrates.  
 
 
          Sherry F. Queener, Ph.D., Chair 
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CHAPTER 1-INTRODUCTION 
 
Propoxyphene, a commonly used analgesic, may inhibit a major metabolizing 
enzyme, CYP3A. CYP3A metabolizes an estimated 60% of marketed drugs and 
endobiotics. CYP3A metabolizes many different types of drugs across multiple chemical 
classes and therapeutic classifications. Inhibition of CYP3A can reduce and prevent 
metabolism of CYP3A substrates, including co-administered drugs and chronically 
administered propoxyphene. Inhibition of CYP3A can lead to higher blood levels of these 
CYP3A substrates, which may cause an increase in reported side effects or adverse 
events. Some reported overdoses of propoxyphene may be attributed to mechanism-based 
inhibition of CYP3A. The purpose of this study was to determine if propoxyphene 
inhibits CYP3A, and, if so, to characterize the inhibition and determine to what extent the 
inhibition may affect patients who take the drug  
Propoxyphene has been prescribed for over fifty years, but has been associated 
with numerous overdoses. Propoxyphene, like other opioids, has high abuse potential and 
is associated with higher rates of self-poisoning than other classes of drugs (Ng and 
Alvear, 1993). Accidental and suicide deaths have been attributed to the drug and its 
metabolite, either alone or in combination with other medications, including alcohol, 
benzodiazepines, acetaminophen, and other painkillers (McBay, 1976). Many cases of 
accidental overdose have been in combination with alcohol or other pain medication due 
to additive central nervous system depression (Gram, 1979) or liver toxicity due to 
acetaminophen overdoses in combined medication (Sheen et al, 2002). Propoxyphene has 
been associated with 2100 reported accidental deaths (38.6% of total propoxyphene 
deaths) in the US from 1981 to 1999, and 7109 total US deaths from 1999 to 2006. It was 
  
                                                                      2 
found as one of the top ten drugs identified during autopsies and implicated in 5.6% of 
drug related deaths from 1981-1999 (DAWN, 2003). Propoxyphene products were 
withdrawn from the market in the United Kingdom in 2006 due to high numbers of 
fatalities at approximately 400 deaths per year (Lister, 2005). Norpropoxyphene, the 
primary metabolite of propoxyphene, has been associated with cardiac deaths in patients, 
and has a long half-life that allows for accumulation in the body (Inturrisi et al, 1982; 
Holland and Steinberg, 1979). Proadifen is structurally similar to propoxyphene and 
norpropoxyphene, but is not a marketed drug.  
Previous reports of adverse events with propoxyphene administration may be 
attributed to mechanism-based inhibition of CYP3A. Mechanism-based inhibition occurs 
when a substrate of an enzyme inhibits it irreversibly during the catalytic cycle, and 
renders the enzyme permanently inactive. Mechanism-based inhibition can result in a 
reduction in the total amount of active enzyme. As the active enzyme pool is reduced, 
fewer substrates may be metabolized until new enzyme is synthesized. As a result, 
substrates accumulate resulting in elevated blood level concentrations represented by area 
under the curve, or AUC. AUCs may be above the desired therapeutic window of 
effectiveness and safety, resulting in toxic concentrations and overdoses. 
Purpose of the study:  
 
The focus of this research was to determine if propoxyphene, norporpoxyphene, 
and proadifen irreversibly inhibit CYP3A4(+b5), CYP3A5(+b5), and CYP3A in human 
liver microsomes in vitro. In vitro reversible inhibition of propoxyphene, 
norpropoxyphene, and proadifen with CYP3A4(+b5), CYP3A5(+b5) and CYP3A in 
human liver microsomes was also assessed. The second part of this research was to 
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determine if irreversible inhibition is due to the formation of a metabolic-intermediate 
complex. Metabolic-intermediate complex formation occurs when an inhibitor 
irreversibly binds to the CYP enzyme during its catalytic cycle, forming a covalent 
complex which is visible spectrophotometrically. 
The in vitro inhibition data were examined comparing the potency of 
propoxyphene, norpropoxyphene, and proadifen for reversible and irreversible inhibition. 
The inhibitors were also compared for potency with the different isozymes (CYP3A4 and 
CYP3A5). The inhibitors were tested for metabolic-intermediate complex formation. 
Finally, the in vitro inhibition data were analyzed in comparison to in vivo blood levels of 
propoxyphene and norpropoxyphene to assess the clinical significance of findings. 
Background information on the compounds used in this study: 
 
Propoxyphene is an analgesic that is frequently prescribed in the United States 
and Europe. It was the seventeenth highest-selling generic drug in the United States in 
2006, and ranked thirty-fourth for total retail dollars spent in 2006 at $260 million (Drug 
Topics, 2007). Marketed under the brand names of Darvon, Distalgesic, Co-proxamol1, 
and Darvocet, propoxyphene is administered alone or in combination with non-steroidal 
anti-inflammatory drugs and/or caffeine to gain synergistic pain relief (Beaver, 1988; 
PDR, 2000).  
Propoxyphene contains two chiral carbon atoms for two pairs of diasteriomers (α-
d,l and β-d,l) (Somogyi et al, 2004) (see Table 1, p37). The β-d,l racemate is 
pharmacologically inactive (Nickander et al, 1984), but the α-d enantiomer 
(dextropropoxyphene) has analgesic properties (Gruber, 1956) and the α-l enantiomer has 
                                                 
1 Co-proxamol was withdrawn from the market in the United Kingdom in January of 2005 due to drug 
related suicides and deaths (Lister, 2005).  
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antitussive properties (Miller et al, 1963). The drug product is composed of the α-d 
enantiomer in a hydrochloride or napsylate salt (AHFS, 2007). Dextropropoxyphene 
relieves pain by targeting opioid receptors in the brain, and is a weak opiate agonist 
(Miller, 1970). Dextropropoxyphene has one-half to two-thirds the potency of codeine 
(Gruber, 1977). Its mechanism of action is similar to other narcotic analgesics, such as 
methadone and codeine, and it shares similar alkylamine chemical structures with these 
other drugs (Somogyi et al, 2004; McMahon, 1961; Feinburg et al, 1976) (Tables 1 and 
2, p37-38).  
Propoxyphene is metabolized by Cytochrome P450 3A (CYP3A) to 
norpropoxyphene (Somogyi et al, 2004). Norpropoxyphene is not a marketed drug, 
although it has analgesic properties and even greater local anesthetic effects than 
propoxyphene (Nickander et al, 1984). Norpropoxyphene is further metabolized to 
dinorpropoxyphene (Nash et al, 1975). Other minor metabolites of propoxyphene and 
norpropoxyphene have been identified, but are not commercially available (McMahon et 
al, 1973; Nash et al, 1975).  
Proadifen has a similar chemical structure and chemical properties to 
propoxyphene and norpropoxyphene (Table 2, p38). These three compounds are tertiary 
alkylamines of similar molecular weight. All three compounds are composed of a 
hydrocarbon chain with an ester, two phenyl substituents, and a di-methylated or di-
ethylated nitrogen (Anders and Mannering, 1966; Somogyi et al, 2004). Unlike 
propoxyphene, proadifen was originally developed by Smith Kline and French, but it is 
not a marketed drug. Proadifen is a potassium channel blocker and a nicotinic 
acetylcholine receptor blocker (Anders and Mannering, 1966; Buening and Franklin, 
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1974). It is metabolized to the de-ethylated product SKF 8742-A (Buening et al, 1974). 
Proadifen has been used as a research tool in animals and in vitro as a general inhibitor of 
drug metabolism (Cook et al, 1954; Anders and Mannering, 1966; Buening and Franklin, 
1974; Jones et al, 2007). Proadifen is a known general cytochrome P450 inhibitor 
(Schenkman et al, 1972; Bensoussan et al, 1995). Proadifen forms a metabolic-inhibitor 
complex with CYP3A4 (Jones et al, 2007), although its inhibition of CYP3A4 and 
CYP3A5 has not been extensively characterized. 
Background information on enzyme inhibition: 
Enzyme inhibition can be categorized as reversible and irreversible2 (Lin, 1998). 
In reversible inhibition, the inhibitor and enzyme bind non-covalently. When the enzyme 
and inhibitor disassociate, the enzyme is still functional. In irreversible inhibition, the 
enzyme-inhibitor bond is usually covalent, the enzyme has been chemically changed, and 
the enzyme is no longer functional after binding to the inhibitor (Lin 1998).  
An overview of irreversible inhibition is summarized in Schematic I (p44). As 
shown, the inhibitor can act as a substrate that is metabolized by the enzyme to a product 
(i.e. metabolite), but the enzyme can also be inactivated by the inhibitor (Silverman, 
1995). Irreversible inhibition common with Cytochrome P450 enzymes (CYPs) is termed 
mechanism-based inhibition (MBI), and occurs when a metabolite is reactive and binds to 
the heme or protein of the CYP that caused its formation (Lin, 1998). The metabolite, or 
product, binds the CYP enzyme covalently, removing it permanently from the active 
enzyme pool so that it can no longer metabolize drugs. The enzyme can only be 
                                                 
2 Some scientists support three types of inhibition including quasi-irreversible inhibition as the third type. 
Quasi-irreversible inhibition is similar to irreversible inhibition except that the inhibitor can become 
unbound from the enzyme in an in vitro setting chemically (with addition of potassium ferrocyanide) or 
using radiation (Lin, 1998).  
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replenished by new synthesis3. Mechanism-based inhibitors may form a metabolic-
inhibitor complex with CYPs that can be detected experimentally at an absorption 
spectrum of approximately 450 nm (Murray, 1997)4. Metabolic-inhibitor complex 
formation with the nitrogen atom of an inhibitor and the iron atom of a CYP molecule is 
proposed in Schematic II (p44). Often alkylamines form a covalent complex with CYPs, 
particularly with CYP3A (Bensoussan et al, 1995). There are several known examples of 
pharmaceuticals that form metabolic-inhibitor complexes with CYP3A enzymes 
including some macrolides (oleandomycin, erythromycin) and some protease inhibitors 
(amprenavir, lopinavir, nelfinavir, ritonavir, and saquinavir) (Polasek and Miners, 2005; 
Ernest et al, 2004). These irreversible inhibitors can reduce the amount of free enzyme 
available to metabolize other drugs, potentially causing adverse reactions.  
During reversible inhibition, the inhibitor binds to the enzyme, the enzyme and 
inhibitor then disassociate, and the enzyme returns to the active enzyme pool. The 
inhibitor or metabolite of the inhibitor does not form a permanent complex with the 
enzyme as occurs in mechanism-based inhibition. As demonstrated by Schematic III 
(p45), an enzyme (E) can bind with an inhibitor (I) to form the reversible enzyme 
inhibitor complex (EI), or the enzyme (E) can bind the substrate (S) to form the enzyme-
substrate complex (ES) which can yield a product (metabolite), or return to free enzyme 
(E) and free substrate (S). The Ki is the dissociation constant for reversible inhibition. Ki 
is a ratio of the amount of free enzyme and inhibitor ([E][I]) to the amount of enzyme and 
inhibitor complex ([EI]) (Stryer, 1996; Zubay, 1998).  
 
                                                 
3 The half life for CYPs in the body is 1-6 days (Dossing, 1983). 
4 Also called an Iron II Metabolite Complex (Naritomi et al, 2004). 
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Background information on enzymes used in this study: 
CYPs are heme-based membrane proteins found in bacteria and animals. 
Eukaryotic CYPs are 480 to 560 amino acids long, and can be found in the endoplasmic 
reticulum, mitochondria, or cytosol of the cell. Microsomes are self-sealing fragments of 
endoplasmic reticulum membranes (Stryer, 1996), and the CYPs found in the 
endoplasmic reticulum of cells are referred to as the microsomal type (Nelson et al, 
1996). Microsomal CYPs were the focus of this study. CYPs are named for their 
absorbance peak at 450 nm, (Danielson, 2002). CYP enzymes can be found in the liver 
(the major site of metabolism) and small intestine, kidney, skin, brain, lungs, gonads, 
adrenal glands, and other tissues (Goodman and Gillman, 1996). CYPs often metabolize 
highly lipophilic drugs into more hydrophilic compounds that can then be more readily 
eliminated from the body in the urine (Danielson, 2002; Goodman and Gillman, 1996).  
CYPs require reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
CYP reductase, NADPH, and molecular oxygen to perform their oxidation/reduction 
reactions to metabolize drugs. NADPH reductase is a membrane protein located near the 
CYP that contributes electrons to the oxidation reaction, NADP(H) serves as a cofactor 
by donating electrons to the reductase, and molecular oxygen can bind the ferric iron of 
the hemoprotein and eventually combine with the leaving group (e.g. N- or O-
Dealkylations reactions) or bind to the parent drug (N- or S-oxidations) (Goodman and 
Gillman, 1996). Although they exist in vivo, CYPs and supporting enzymes, and 
cofactors (CYP reductase, and cytochrome b5, another electron donating group5), have 
                                                 
5 The proposed mechanism of reduced cytochrome b5 in CYP oxidation-reduction reactions is to transfer 
electrons to P450 after being reduced by NADPH-P450 reductase (Yamazaki et al, 1996). It can interact 
synergistically to boost catalytic efficiency of CYPs (Danielson, 2002).  
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been recombinantly expressed in bacculovirus cells for in vitro testing (Crespi and 
Penman, 1997). 
Thirty different cytochrome P450 enzymes have been identified including twelve 
families of CYPs in humans (Williams et al, 2004). CYPs with greater than 40% amino 
acid identity belong to the same family (Danielson, 2002). Of all the human CYPs, the 
CYP3A family is one of the most important for drug metabolism. The CYP3A family in 
humans metabolizes endobiotics such as testosterone and progesterone (Niwa et al, 1998) 
and approximately sixty percent or more of marketed drugs (Wrighton et al, 1990), 
including propoxyphene (Chow et al, 2006).  
CYP3A performs N-demethylation and hydroxylation reactions. Propoxyphene 
and norpropoxyphene are metabolized by CYP3A in the liver to norpropoxyphene and 
dinorpropoxyphene, respectively (Somogyi et al, McMahon et al, 1973; Nash et al, 
1975). Compared to other CYP families, the CYP3A family metabolizes drugs with the 
largest molecular size (Nagata and Yamazol, 2002). CYP3A is the most abundant CYP in 
the liver and small intestine (Yamazaki et al, 1996); its expression level is thirty to sixty 
percent of the total CYP content in the human liver (Shimada et al, 1994) and comprises 
sixty to seventy percent of the CYP in the small intestine (Anttila, 1997). The enzymes 
CYP3A4, CYP3A5, CYP3A7, and CYP3A43 make up the CYP3A family in humans 
(Wrighton et al, 2000). 
CYP3A4 and CYP3A5 share an eighty-three percent amino acid sequence 
identity (Aoyama et al, 1989). These two enzymes have similar substrate specificity (Lin 
et al, 2002), with CYP3A5 generally exhibiting a lower metabolic capability than 
CYP3A4 (Williams et al, 2002). Most of the general population expresses CYP3A4 
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despite the existence of genetic polymorphisms. Keshava et al, (2004) found that 
polymorphisms in CYP3A4 do not contribute to differences in activity. Although Dai et 
al, (2001) found three genotypes associated with differential CYP3A4 expression, *17, 
*18, and *1B. The CYP3A4*17 genotype corresponds with reduced CYP3A4 expression, 
and the CYP3A4*18 corresponds with increased CYP3A4 expression as compared with 
wildtype *1 (Dai et al, 2001), (Table 3, p39). Contradictory results have been reported 
for CYP3A4*1B. CYP3A4*1B expression is associated with increased CYP3A4 activity 
over wildtype (Kuehl, 2001). CYP3A4*1B is associated with reduced CYP3A4 
expression (Wojnoski et al, 2002).CYP3A4 is generally considered the most abundant 
CYP in the liver and the small intestine (Shimada et al, 1994). Unlike CYP3A4, CYP3A5 
is expressed in the kidney (Eichelman and Burk, 2001), and is the predominant CYP in 
the lung (Attila, 1997).  
CYP3A5 is polymorphic and includes individuals who do not produce functional 
CYP3A5 enzyme. CYP3A5 is only detectable in twenty to thirty percent of human livers 
(Eichelbaum and Burk, 2001). Ten to thirty percent of Caucasians, fifty-five to seventy 
percent of Black Africans and African Americans, and thirty-three percent of the 
Japanese express CYP3A5 (Kamden et al, 2005). Several alleles have been identified for 
CYP3A5; *1, *2, *3, *5, *6, and *7. The *1 allele is the wildtype allele. The presence of 
one *1 allele contributes to high expression of CYP3A5. CYP3A5*1 produces ten to 
thirty times the amount of CYP protein produced from CYP*3/*3 (Kreutz et al, 2005). In 
human liver microsomes, Huang et al, (2004) found that individuals carrying the 
CYP3A5*1 allele, CYP3A5 constituted more than 50% of the total CYP3A expression. 
Polymorphisms in CYP3A5 can be a causal factor in differential patient responses to 
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drugs and food products. Chow et al, (2006) found that poor CYP3A5 expressers 
(CYP3A5*3/*3) had higher propoxyphene plasma concentrations and lower clearance 
rates of propoxyphene than expressers (CYP3A5*1/*3 or CYP3A5*1/*1). CYP3A7 and 
CYP3A43 are enzymes that have been found in very low levels in some adult livers 
(Gellner et. al., 2001), and CYP3A7 is predominantly a fetal enzyme (Thummel and 
Wilkinson, 1998). For these reasons, only the CYP3A4 and CYP3A5 enzymes of the 
CYP3A family are examined along with pooled human liver microsomes.  
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CHAPTER 2-MATERIALS AND METHODS 
 
An overview of methods used in this study: 
Propoxyphene, norpropoxyphene, and proadifen were incubated with recombinant 
CYP3A4 and recombinant CYP3A5 recombinant or pooled human liver microsomes. 
Formation of 6β hydroxy testosterone, the major metabolite of testosterone, was 
quantified with HPLC. Kinetic parameters were estimated from data fit with Windows 
NonLin non-linear regression data models (version 5.0.1, Pharsight, Mountain View, 
California). Kinetic parameters calculated from the experimental inhibition data were 
used to estimate in vivo changes in area under the plasma concentration time curve, AUC. 
Metabolite complexes were detected by ultraviolet/visible spectrophotometry, based upon 
an absorption maximum of 450 nm.  
Chemicals: 
Propoxyphene hydrochloride was obtained from the United States Pharmacopeia 
(Rockville, Maryland). Norpropoxyphene HCl, testosterone, 6β-hydroxytestosterone, 
desmethyl diazepam, temazepam, ammonium acetate, and NADPH were purchased from 
Sigma-Aldrich (St. Louis, Missouri). HPLC grade acetonitrile (ACN) and methanol were 
purchased from J.T. Baker (Phillipsburg, New Jersey), and HPLC grade ethyl acetate was 
purchased from EMD Chemicals, Inc. (Gibbstown, New Jersey). 
Enzymes: 
Recombinant CYP3A4(+b5) and recombinant CYP3A5(+b5) were purchased 
from BD Gentest (Woburn, Massachusetts). Adult human liver microsomes were 
prepared from human liver tissues (in accordance with protocols approved by the 
Institutional Review Board of IUPUI ). The homogenates of five livers were pooled at 20 
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mg/ml total protein yielding a CYP concentration of 0.3 nmol/mg protein. (Lowery et al, 
1951; Gorski et al, 1994).  
Mechanism-Based (Irreversible) Inhibition Experiments: 
Enzyme inhibition was determined by the time-dependent and concentration-
dependent loss of 6β-hydroxy-testosterone product formed from testosterone by 
CYP3A4(+b5), CYP3A5(+b5), or human liver microsomes. The inhibitor was diluted in 
methanol and subsequently diluted in phosphate buffer (with 5 mM MgCl2, pH 7.4) for a 
final concentration of < 0.5 % methanol or evaporated to dryness prior to incubation with 
human liver microsomes (100 µg total protein), CYP3A4(+b5) (20 pmoles), or 
CYP3A5(+b5) (20 pmoles). The reaction was started with 5 µl of 10 mM NADPH made 
with phosphate buffer for a final pre-incubation6 reaction volume of 50 µl at 37 °C in a 
mixing waterbath. Inhibitor concentrations and inhibitor incubation times were 
determined from preliminary experiments of single data points. Final pre-incubation 
experiments were conducted with samples in duplicate. 
 Immediately following the pre-incubation of inhibitor and enzyme, 950 µL of 
incubation supplement mixture (containing phosphate buffer as described above, 250 
µM7 testosterone (substrate), and 10 mM NADPH) were added to the tubes in 37 °C 
water bath for an additional two minute incubation. The reaction was quenched with two 
mL ice-cold ACN. The internal standard, desmethyl diazepam or temazepam (600 ng), 
was added and the reaction tubes were mixed on a vortex mixer for 30 seconds and 
centrifuged at 2500 rpm for 5 minutes. The supernatant was removed from the protein 
                                                 
6 Pre-incubation refers to the incubation reaction of the inhibitor, enzyme, and NADPH, prior to the 
addition of substrate.  
7 The concentration of testosterone was well above the Vmax for 6β hydroxyl testosterone formation with 
CYP3A4(+b5), CYP3A5(+b5), and HLM.  
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and added to glass screw-top tubes containing 5 ml of ethyl acetate. The tubes were 
shaken for 30 minutes and then centrifuged at 2500 rpm for 5 minutes. The organic layer 
was removed and transferred to 13x100 mm glass culture tubes and evaporated to 
dryness. That residue was reconstituted with 250 µl mobile phase (40% 30mM 
Ammonium acetate, pH 6.4: 60% methanol (volume per volume)). Concentrations of 6β-
hydroxy testosterone were determined using HPLC with 5 µm C-18(2) Luna 
Phenomenex (Torrance, California) column with a 1 ml/min flow rate and uv detection at 
254 nm.  
Reversible Inhibition Experiments: 
To test for reversible inhibition, inhibitor and testosterone were diluted in 
methanol and subsequently diluted in phosphate buffer (with 5 mM MgCl2, pH 7.4), for a 
final concentration of < 0.5 % methanol, or evaporated to dryness in tubes prior to 
incubation. Enzyme, substrate, inhibitor and phosphate buffer were combined for a total 
volume of 900 µL, and 100 µL of 10 mM NADPH solution were added to start the 
reaction. The tubes were incubated for two minutes in a 37 °C mixing water bath. The 
reaction was quenched with two mL ice-cold ACN and subsequent extraction and 
analysis steps were performed (as described above). The concentration of substrate and 
inhibitor used to calculate Ki values were estimated from preliminary experiments with 
single samples (see Data Modeling section below). Final experiments were conducted 
with samples in duplicate. A minimum of four concentrations of testosterone were tested, 
two concentrations above the Km and two concentrations below the Km for each enzyme. 
Each inhibitor was tested with at least two concentrations above and two concentrations 
below the estimated Ki value (from preliminary data).  
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Metabolic-Inhibitor Complex Formation Experiments: 
Initial metabolic-inhibitor complex experiments were conducted with a dual beam 
spectrophotometer (Uvicon 933, Research Instruments). Two 1 mL cuvettes were 
prepared with 100-200µL enzyme (100-200 pmoles CYP3A4(+b5) or CYP3A5(+b5) and 
1 mg of total protein of human liver microsomes), 5 µL of 1 mg/mL8 inhibitor in 
methanol (or methanol for reference), and 0.1 M phosphate buffer with 5 mM magnesium 
chloride each at 37 °C. 100 µL of 10 mM NADPH were added to start the reaction (1 mL 
total reaction volume). Wavelengths 380-500 nm were scanned at time zero and then at 
two or five minute intervals, the samples were assessed for an absorbance maximum by 
subtracting the absorbance at 490 nm from the difference of the absorbance scan at each 
timepoint and a background absorbance scan. The metabolic-inhibitor complex forms as 
a characteristic peak at approximately 450 nm that increases with absorbance over time. 
The method to detect metabolic-inhibitor complex was adapted for a microplate reader 
(Synergy™ 2, BioTek) for follow-up experiments. In these experiments, 80 µL of 
enzyme and 260 µL of phosphate buffer (as described above) were combined in a 
polypropylene tube. Next, 170 µL of enzyme and buffer mixture were aliquoted into each 
well (experimental and control well). The plate was warmed at 37 °C for two to three 
minutes, and then 10 µL of inhibitor (in a 1 mg/mL solution of 10% methanol and 90% 
phosphate buffer) were added to the first well, and 10 µL of 10% methanol 90% 
phosphate buffer were added to the reference well. The reaction started with the addition 
of 20 µL 10 mM NADPH (Pershing and Franklin, 1982).  
 
                                                 
8 This corresponds to a concentration of approximately 15µM for each.  
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Data Modeling for Inhibition: 
The percentage of enzyme activity remaining after incubation was determined by 
the amount of 6β-hydroxy testosterone formed relative to the amount formed at 0 time 
(100%) at each inhibitor concentration. The natural logarithm of percent activity was 
plotted against pre-incubation time at different inhibitor concentrations. The lines of best 
fit were determined using Microsoft Excel best fit trendline. The slopes of these lines 
were used to determine kobserved values, or the observed rate of 6β-hydroxy testosterone 
product decline, at various inhibitor concentrations. Inhibitor pre-incubation time and 
percent activity (Et) at various concentrations of inhibitor were modeled with Windows 
Nonlin Professional to estimate kinact, the rate constant for maximal rate of inactivation, 
and KI, the concentration of substrate at half maximal inactivation (Equation 1, p46). 
From the Windows Nonlin Professional KI and kinact estimates, kobserved was calculated 
and plotted as a hyperbolic curve (see Equations 2a and 2b). The standard error of the 
mean (SE), coefficient of variation (CV), Akaike Information Criterion (AIC), and 
Schwartz Bayesian Criterion (SBC) were used to evaluate each model for best fit. 
Information on the statistical criteria can be found in the Appendix.  
For reversible inhibition, 6β-hydroxy testosterone/min product formation data 
were modeled with Windows Nonlin Professional. The models estimated Vmax, Km, and 
Ki values. The Vmax is the maximal velocity of product formation that can be achieved by 
increasing substrate concentration under the conditions of assay. Preliminary reversible 
and irreversible inhibition experiments were conducted using singlet data points across 
multiple concentrations of inhibitor. Experiments were conducted in duplicate and data 
were modeled in competitive, noncompetitive, and uncompetitive inhibition models (see 
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Equations 3-5, p46). Inhibition type was determined based on best fit criteria from model 
(lowest SE9, CV, AIC, SBC). Final experiments were conducted in duplicate using a 
minimum of two concentrations below and two concentrations above the estimated Ki 
value.  
Experimental Predictions of In Vivo Drug Interactions with Propoxyphene and 
Norpropoxyphene:  
The in vivo AUC'po/AUCpo of common CYP3A substrates was estimated using 
Equation 6 (p46) (Wang et al, 2005). FG is the intestinal wall bioavailability (Wang, 
2005), and was determined from published data. F’G is the intestinal wall bioavailability 
in the presence of the inhibitor. The kinact and KI values were determined from 
experiments with human liver microsomes. Iu is the average unbound steady state 
concentration of each inhibitor. The kdeg values, or rate of enzyme degradation, are 
0.00128 and 0.00026 min-1 based on rat CYP3A and human CYP3A4 in CaCO-2 cells 
(Correia, 1991; Malhotra et al, 2001). Both rates of enzyme degradation were used in the 
calculation resulting in a range estimates for the AUC'po/AUCpo. The equation assumes a 
maximal inhibition of CYP3A by propoxyphene or norpropoxyphene from the gut wall, 
and F’G is equal to 1 (consistent with Wang et al, 2005 and Ernest et al, 2004). The total 
CYP3A hepatic elimination of the substrate without inhibitor (fm) was determined from 
published in vivo data.  
 
                                                 
9 See Appendix for more information on statistical criteria used to evaluate inhibition models. 
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CHAPTER 3-RESULTS 
Chromatography Data: 
For incubations with CYP3A4(+b5) or CYP3A5(+b5), a mobile phase of 40% 30 
mM ammonium acetate (pH 6.3-6.4) was used with desmethyldiazepam or temazepam as 
internal standards. Non-extracted standards (6β-hydroxy testosterone, internal standard, 
testosterone), and inhibitors were analyzed by HPLC prior to use in an incubation to 
verify peak separation and recovery (Figure 1, p47). In some preliminary experiments, 
metabolite peaks co-eluted with one internal standard, which necessitated the use of the 
other internal standard for subsequent incubations. The human liver microsomes 
incubation with testosterone and propoxyphene, norpropoxyphene, or proadifen often 
resulted in peaks that co-eluted with 6β-hydroxy testosterone and/or both internal 
standards. The mobile phase was adjusted by increasing the percentage of ammonium 
acetate and decreasing the percentage of methanol to improve separation, although this 
increased the run time. Subsequently, the pH of ammonium acetate was adjusted to 
improve separation and reduce run time. A final mobile phase of 50% ammonium acetate 
pH 5.6-5.8 and 50% methanol was used for human liver microsomes incubations to 
improve peak separation (Figure 2, p48).  
Irreversible Enzyme Inhibition Data: 
Propoxyphene, norpropoxyphene, and proadifen exhibited time and concentration 
dependent inactivation of CYP3A4(+b5), CYP3A5(+b5), and CYP3A with human liver 
microsomes (see Table 4, p40). The lowest KI was achieved by proadifen and 
CYP3A4(+b5) (0.35 µM). Propoxyphene and human liver microsomes generated the 
second lowest KI (0.45 µM). All three compounds were less potent inhibitors of 
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CYP3A5(+b5) than CYP3A4(+b5) based on KI values. The KI values with CYP3A5(+b5) 
were three to sixty times higher than corresponding values with CYP3A4(+b5) and three 
to thirty times higher than with human liver microsomes. The KI values for 
propoxyphene with human liver microsomes were lower than the KI values of 
propoxyphene with CYP3A4(+b5) and CYP3A5(+b5). Norpropoxyphene exhibited 
inactivation (KI values) with CYP3A4(+b5) and human liver microsomes at similar 
concentrations. Proadifen was a more potent inhibitor of CYP3A4(+b5) than human liver 
microsomes (KI values were 0.35 and 6.9 µM, respectively).  
Proadifen exhibited irreversible inhibition of CYP3A4(+b5), CYP3A(+b5), and 
CYP3A in human liver microsomes. The KI values for proadifen and CYP3A5(+b5) were 
approximately three-fold higher than the KI values for proadifen and human liver 
microsomes. The rates of enzyme inactivation are summarized in Table 4, p40. 
Propoxyphene and norpropoxyphene exhibited the highest rates of inactivation (highest 
kinact) with CYP3A4(+b5), 0.41 min-1and 0.56 min-1, respectively. The highest kinact of all 
three compounds with CYP3A5(+b5) was achieved by norpropoxyphene (0.21 min-1). 
The rates of inactivation for proadifen and CYP3A4(+b5) and proadifen and human liver 
microsomes were similar (0.26 min-1 and 0.20 min-1, respectively).  
The results of irreversible inhibition experiments are plotted in Figures 3-29 (p49-
75). These include graphs of % Activity v. Pre-incubation Time, kobs v. Inhibitor, and % 
Activity Relative to Control. The percent activity versus pre-incubation time graphs 
include the averaged data points and lines calculated from model estimates, these are 
listed in Figures 3-11 (p49-57). Although the pre-incubation times differ, the plots 
demonstrate that activity decreases as pre-incubation time increases, and activity 
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decreases with increasing concentrations of inhibitor. The lines in Figures 3-11 were 
calculated from Equation 2b (p46) with kinact and KI model estimates. Although not all % 
activity data points fall on the line, the general trend of the data for each concentration is 
similar to the predicted line shown in the graph. The slopes of excel best fit lines from 
Figures 3-11 which represent kobserved, were plotted versus inhibitor concentration in 
Figures 12-20 (p58-66). The hyperbolic curve was calculated (Equation 2a, p46) based 
on kinact and KI model estimates using percent activity.  
Figures 21-29 (p67-75) show percent of control enzyme activity remaining using 
pre-incubation for control or inhibitor reactions. The concentrations of inhibitor are listed 
across the x-axis as inhibitor concentration in the total incubation mix (1 mL reaction)10. 
Only norpropoxyphene and CYP3A5(+b5) showed a decrease in % activity relative to 
control below 75% in these experiments performed without pre-incubation 
(approximately 70% activity at 4 µM norpropoxyphene, Figure 25, p71).  
Metabolic-Inhibitor Complex Formation Data: 
Propoxyphene, norpropoxyphene, and proadifen formed metabolic-inhibitor 
complexes with CYP3A4(+b5) and CYP3A5(+b5) (see Figure 30, p76 for a metabolic-
inhibitor complex plot, and Table 4, p40 for metabolic-inhibitor complex formation 
results for each compound and enzyme). In initial studies with the dual beam 
spectrophotometer and CYP3A5(+b5) enzyme, only propoxyphene and proadifen formed 
a metabolic-inhibitor complex with CYP3A5(+b5). Norpropoxyphene had been tested for 
metabolic-inhibitor complex formation with CYP3A5(+b5) before the KI was determined 
by pre-incubation experiments, and the concentration may have been too low to form a 
                                                 
10Although this control is not pre-incubated with NADPH prior to the addition of substrate, the total 
concentration of inhibitor in a 50 µL pre-incubation reaction is listed in parentheses, for ease of 
comparison to pre-incubated samples. 
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metabolic-inhibitor complex (norpropoxyphene was tested at 15.3 µM, the KI was later 
determined to be 25.2 µM). In follow up experiments with the plate reader, 
norpropoxyphene was tested at a higher concentration (153 µM) and formed a metabolic-
inhibitor complex with CYP3A5(+b5). Propoxyphene and norpropoxyphene did not form 
a metabolic-inhibitor complex with human liver microsomes, although proadifen did 
form a metabolic-inhibitor complex with human liver microsomes.  
Reversible Enzyme Inhibition Data: 
Propoxyphene, norpropoxyphene, and proadifen exhibited reversible inhibition of 
CYP3A4(+b5), but proadifen was the most potent inhibitor (Ki value was 5 µM) (Table 
5, p41). Propoxyphene and norpropoxyphene exhibited reversible inhibition of 
CYP3A4(+b5) only at higher concentrations (Ki values were 26 µM and 29 µM, 
respectively). Proadifen was the most potent reversible inhibitor of CYP3A5(+b5) and 
human liver microsomes, with Ki values of 12 µM and 8 µM, repectively. 
Norpropoxyphene exhibited reversible inhibition of human liver microsomes (Ki value 
was 59 µM), but the estimated Ki value of propoxyphene (155 µM) was higher than the 
highest concentration tested (80µM). The Ki estimates for propoxyphene or 
norpropoxyphene and CYP3A5(+b5) were also above the highest concentration tested 
(100 µM). For propoxyphene and CYP3A4(+b5), the competitive model had the lowest 
SE, CV, AIC, and SBC. For all compounds and enzymes studied, the competitive model 
yielded the best fit of the data and the lowest overall values for SE, CV, AIC, and SBC.  
A Comparison of Irreversible and Reversible Enzyme Inhibition Data: 
Propropoxyphene and norpropoxyphene were more potent irreversible inhibitors 
than reversible inhibitors. The Ki value for propoxyphene and CYP3A4(+b5) is twenty 
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times higher than the KI value, and the Ki value for propoxyphene and human liver 
microsomes is over one hundred and eighty times higher than the KI value. For 
propoxyphene and CYP3A5(+b5), the Ki value is more than seven times higher than the 
KI value For norpropoxyphene, the Ki value of CYP3A4(+b5) was three times higher 
than KI values, and the Ki value for human liver microsomes was seven times higher than 
the KI value. Although the Ki value for norpropoxyphene could not be determined, the Ki 
value is greater than four times the value of KI value. Unlike propoxyphene and 
norpropoxyphene, proadifen achieved similar concentrations for Ki value and KI value 
with human liver microsomes and CYP3A5(+b5). The Ki value and KI value for 
proadifen and human liver microsomes are 8 µM and 7 µM, respectively. The Ki value 
and KI value for proadifen and CYP3A5(+b5) are 20 µM and 12 µM, respectively. 
Irreversible inhibition (KI value) of CYP3A4(+b5) was ten times greater than reversible 
inhibition (Ki value) with proadifen, KI value was 0.4 µM and Ki value was 5 µM (Tables 
4 and 5, p40-41). The Ki values of proadifen with CYP3A5(+b5) and human liver 
microsomes are twelve and eight, respectively, and KI values are twenty and seven, 
respectively. The Ki value for proadifen and CYP3A4(+b5) is about fourteen times the KI 
value.  
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CHAPTER 4-DISCUSSION 
 
The results are discussed relative to the distribution of propoxyphene in the body, 
enzyme selectivity, reversible and irreversible inhibition, in vivo propoxyphene and 
norpropoxyphene concentrations, and drug-drug interactions with other CYP3A 
substrates. Proadifen results will also be mentioned. 
After oral administration, propoxyphene is rapidly distributed to the liver, brain, 
lungs, and kidneys, and is eliminated as propoxyphene or metabolized product 
(norpropoxyphene or dinorpropoxyphene) in the urine (Clark, 1986). However, orally-
administered propoxyphene must pass through the small intestine and liver before 
distributing to the rest of the body11, and is therefore subject to “first-pass” metabolism 
(Ferrier, 1972). Only eighteen percent of propoxyphene enters the systemic circulation 
from the oral administration of a 65 mg dose of propoxyphene hydrochloride (Ferrier, 
1972). Propoxyphene and norpropoxyphene can be metabolized by CYP3A in the small 
intestine and liver to dinorpropoxyphene, and/or be irreversibly bound to CYP3A 
enzymes. CYP3A4 is the most abundant CYP in the liver and small intestine, where 
CYP3A5 is also found (Shimada et al, 1994), although functional protein is only 
expressed in some individuals (Kamden et al, 2005; Huang et al, 2004). Propoxyphene or 
norpropoxyphene that reaches the systemic circulation may be metabolized by CYP3A5 
in the kidney (Eichelman and Burk, 2001). Selectivity of CYP3A5 over CYP3A4 would 
be important to know, as CYP3A4 and CYP3A5 vary in interpersonal expression of 
functional enzyme and distribution in the body.  
                                                 
11 The drug is most often taken orally because intravenous and subcutaneous administration result in 
severe vein and soft tissue damage (Hudson, 1977). Oral administration is also more convenient than i.v. 
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Propoxyphene is a more potent mechanism-based inhibitor of CYP3A4 than of 
CYP3A5, with KI’s approximately ten times higher for CYP3A4 than CYP3A5 (Table 4, 
p40). In fact, propoxyphene, norpropoxyphene, and even proadifen were more potent 
irreversible inhibitors of CYP3A4 than CYP3A5 based on KI’s. CYP3A5 generally 
exhibits a lower metabolic capability than CYP3A4 (Williams et al, 2002), but there are 
exceptions, such as vincristine and tacrolimus, which are metabolized by CYP3A4 and 
CYP3A5 with equal efficiency12 (Dennison et al, 2007; Kamden et al, 2005). 
Compounds exhibiting higher catalytic rates of metabolism with CYP3A5 than with 
CYP3A4 may show increased toxicity in patients who do not express functional 
CYP3A5. Additionally these compounds may exhibit reduced efficacy due to lower 
blood levels in patients who express high levels of functional CYP3A5. The clearance 
rates of tacrolimus and vincristine increased in CYP3A5 high expressers as compared 
with low expressers (McPhee et al, 2002; Dennison et al, 2007). Increased adverse events 
have been associated in cancer patients taking vincristine who have low CYP3A5-
mediated metabolism as compared to patients with functional CYP3A5 (Dennison et al, 
2007).  
Patients who express functional CYP3A5 and CYP3A4 may exhibit different 
drug plasma concentrations and clearance rates than patients who do not express 
functional CYP3A5, depending on the drug. Individuals expressing functional CYP3A5 
(and CYP3A4) possess two enzymes capable of metabolizing one substrate. Chow et al 
(2006) found that poor CYP3A5 expressers (CYP3A5*3/*3) had higher propoxyphene 
plasma concentrations and lower propoxyphene clearance rates than high expressers 
                                                 
12 The metabolic capability or efficiency of isozymes can be compared by clearance rates (Williams et 
al, 2002).  
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(CYP3A5*1/*3 or CYP3A5*1/*1). It is reasonable to conclude that CYP3A5 high 
expressers (CYP3A5*1/*1) may be less susceptible to propoxyphene-related adverse 
events, despite propoxyphene’s selectivity for CYP3A4 over CYP3A5. 
Polymorphisms in CYP3A4 may also affect the clearance and concentration of 
CYP3A substrates. In vivo metabolism of 3A4 substrates may vary up to ten-fold because 
of differences in CYP3A4 expression (Danielson, 2002). CYP3A4*17, CYP3A4*18, and 
CYP3A4*1B alleles are associated with differential CYP3A4 expression as compared to 
wildtype (CYP3A4*1, and propoxyphene and norpropoxyphene concentrations may vary 
in individuals based on CYP3A4 genotype (Dai et al, 2001; Kuehl, 2001). The 
CYP3A4*17 genotype corresponds with reduced CYP3A4 expression. Accordingly, 
AUCs for propoxyphene and norpropoxyphene may be higher in individuals that have 
this genotype, and they may experience an increased incidence of adverse events. 
Because CYP3A expression and metabolism studies with CYP3A4*1B alleles have 
produced contradictory results, it is difficult to predict the extent of drug interactions with 
this genotype. Findings include CYP3A4*1B producing two-fold increased CYP3A 
activity over wildtype (Kadlubar, 2003), no change in CYP3A4 expression with 
CYP3A4*1B alleles, and no change in midazolam clearance as compared to wildtype 
CYP3A4*1 (Rebbeck, 2000). The CYP3A*1B allele is in linkage disequilibrium with the 
CYP3A5 high expression allele (CYP3A5*1), and high CYP3A5 expression may 
confound CYP3A drug metabolism results.13 Propoxyphene and norpropoxyphene blood 
concentrations may be lower in individuals with the CYP3A4*18 genotype, which 
corresponds with increased CYP3A4 expression (Dai et al, 2001).  
                                                 
13 The non random association of genes at more than one loci. 80% of Caucasians with CYP3A4*1B 
allele also possessed one CYP3A5*1A allele (Wojoski et al, 2002).  
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Despite the existence of CYP3A4 and CYP3A5 polymorphisms in the general 
population, one would expect in vivo studies to support the in vitro observations that 
propoxyphene inhibits CYP3A metabolism. The studies by Inturrisi et al (1982) support 
the assertion that propoxyphene (and norpropoxyphene) are possibly mechanism-based 
inhibitors of CYP3A. Inturrisi et al (1982) reported that repeated dosing of propoxyphene 
resulted in the accumulation of propoxyphene and norpropoxyphene in patients, and 
blood concentrations of propoxyphene and norpropoxyphene were five to seven times 
higher than the concentrations achieved after a single dose. They also found that the 
clearance of propoxyphene and norpropoxyphene decreased with repeated dosing (994 to 
508 mL/min and 454 to 210 mL/min, respectively). Inturrisi et al (1982) found that the 
half life of the two compounds increased from 3.3 to 11.8 hours for propoxyphene, and 
from 6.1 to 39.2 hours for norpropoxyphene with repeated dosing. These characteristics 
may be attributed to a mechanism-based inhibitor. As CYP3A enzymes are irreversibly 
inhibited by propoxyphene and norpropoxyphene, the free enzyme pool is depleted, and 
these compounds may accumulate.  
Propoxyphene, norpropoxyphene, and proadifen are mechanism-based inhibitors 
of CYP3A as measured by inhibition of CYP3A4(+b5), CYP3A5(+b5), and CYP3A in 
human liver microsomes. Propoxyphene and norpropoxyphene form metabolic-inhibitor 
complexes with CYP3A4(+b5) and CYP3A5(+b5), but proadifen formed metabolic-
inhibitor complexes with the recombinant CYPs and human liver microsomes. Ernest et 
al (2004) observed similar results with protease inhibitors; metabolic-inhibitor complex 
formation occurred with protease inhibitors and CYP3A4(+b5), but not with human liver 
microsomes. The pooled liver microsomes express CYP3A4 and CYP3A5 (Wang, 2005), 
  
                                                                      26 
but the lack of metabolic-inhibitor complex formation could be attributed to the low 
amount of CYP3A compared to total protein in human liver microsomes. The pooled 
livers contained approximately three hundred pmoles of CYP (Gorski et al, 1994), and 
approximately thirty pmoles of CYP3A enzyme per mg of total protein (Wang et al, 
2005). The concentration of CYP3A in human liver microsomes is near the limit of 
quantitation of twenty-three pmoles (Ernest, 2004). Proadifen is a general CYP inhibitor 
(Bensoussan et al, 1995) and may bind irreversibly to multiple CYPs, therefore it is not 
surprising that it forms a metabolic-inhibitor complex with human liver microsomes. The 
binding spectra (450 nm) of other CYPs may resemble the binding spectra of CYP3A. 
CYP2D6 and paroxetine form a metabolic-inhibitor complex at approximately 450 nm 
(Bertelsen, 2003). Additionally, proadifen forms a metabolic-intermediate-complex with 
guinea pig CYP2B6 which may resemble the CYP3A4 spectra (Yamada et al, 1992). 
Therefore it is reasonable that proadifen would form a metabolic-inhibitor complex with 
human liver microsomes, and propoxyphene and norpropoxyphene did not form a 
metabolic-inhibitor complex with human liver microsomes. 
Propoxyphene and norpropoxyphene are weak reversible inhibitors of CYP3A, 
with KI values greater than or equal to 26 µM. Many Ki value estimates were greater than 
the highest concentrations tested (≥ 80 µM), much higher than drug concentrations in 
plasma (propoxyphene and CYP3A5(+b5), norpropoxyphene and CYP3A5(+b5), and 
propoxyphene and human liver microsomes).  
Propoxyphene and norpropoxyphene were more potent irreversible inhibitors than 
reversible inhibitors of CYP3A4(+b5), CYP3A5(+b5), and CYP3A in human liver 
microsomes. Because irreversible inhibition removes functional enzyme from the enzyme 
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pool, much of the CYP3A functional protein would theoretically be removed. The KI 
values (inhibitor concentration at half kinact) were at least three times lower than the Ki 
values (concentration of enzyme-inhibitor relative to free enzyme and free inhibitor) for 
CYP3A4(+b5), CYP3A5(+b5), and human liver microsomes for propoxyphene and 
norpropoxyphene. The reported therapeutic blood concentrations of propoxyphene are 
listed in Table 6 (p42) and range from 0.4 to 2.5 µM. The KI value for propoxyphene (~1 
µM) is within range of reported therapeutic blood levels, whereas the Ki value is much 
higher (~50 µM). Therefore propoxyphene concentrations in the body would not 
approach the levels needed for reversible inhibition based on in vitro data. The toxic 
blood concentrations of propoxyphene are greater than 1.5 µM, which closely 
corresponds to the KI value for CYP3A4 (Merck, 2007). The reported therapeutic 
concentrations of norpropoxyphene in blood range from 0.9-15 µM (Verbeley and 
Inturrissi, 1973; Inturrisi et al, 1982). These concentrations are within the range of KI 
value for norpropoxyphene (~8 µM), whereas the Ki value for norpropoxyphene is 
approximately 40 µM. Norpropoxyphene blood concentrations would not approach the 
levels needed for reversible inhibition based on in vitro data. In vivo inhibition of CYP3A 
enzymes would probably be due to mechanism-based inhibition and not due to reversible 
inhibition. 
Norpropoxyphene may play a significant role in adverse events attributed to 
propoxyphene because it has potent anesthetic properties and causes cardiac toxicity and 
seizures (Nickander et al, 1984). Approximately seventy-six percent of propoxyphene 
deaths are attributed to cardiac toxicity (Whitcomb et al, 1989). Norproxyphene causes 
hypotension, decreased contractability, and interruption of cardiac conduction (Holland 
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and Steinberg, 1979). Propoxyphene and norpropoxyphene have anti-arrhythmic 
properties and block sodium channels, but norpropoxyphene is more potent than 
propoxyphene for cardiac effects (Holland and Steinberg, 1979; Slywka, 1975). 
Norpropoxyphene also has a longer half life than propoxyphene (30-36 hours versus 6-12 
hours), and can accumulate in the body. Norpropoxyphene blood concentrations as high 
as 15 µM have been found after high oral therapeutic doses of propoxyphene (Inturrisi et 
al, 1982). Toxicity for norpropoxyphene has not been established, but toxicity has been 
associated with blood concentrations of 0.15 µM propoxyphene (see Table 6, p42).  
Inhibition of CYP3A by propoxyphene may cause adverse effects in patients 
taking high doses of this drug. CYP3A inhibition of propoxyphene may also result in 
adverse affects in patients concomitantly administered other CYP3A substrates. The use 
of propoxyphene in elderly patients is limited because of the high number of reported 
adverse events with propoxyphene in this subpopulation (Beers, 1997), who are often 
administered multiple drugs over the same time period (polypharmacy) as compared to 
other subpopulations14. Potential drug-drug interactions exist for propoxyphene and other 
CYP3A substrates. Mechanism-based inhibition of CYP3A by propoxyphene may 
increase the concentrations of other CYP3A substrates in the body.15 CYP3A metabolizes 
up to 60% of marketed drugs including some immunosuppressants, heart medications, 
and many other drugs (Turgeon et al, 1992; Wang et al, 2005). Other CYP3A substrates 
include food products such as caffeine (Tassaneeyakul et al, 1993), and grapefruit juice 
(Bailey et al, 1993). Increased plasma concentrations of CYP3A substrates (drugs or 
                                                 
14 The elderly also often have decreased liver function compared to the general population. 
15 Some drugs are metabolized by multiple CYP isoforms, and co-administration with propoxyphene may 
not result in higher blood levels. An example is acetaminophen, which is metabolized to N-acetyl-p-
benzoquinone imine by CYP2E1, CYP1A2, CYP2A6, CYP2D6, and CYP3A4 (Dong et al, 2001). 
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metabolites) can elicit severe adverse events, such as rhabdomyolysis, with high plasma 
levels of HMG-CoA reductase inhibitors (Dresser et al, 2000) and sedation with 
benzodiazepines (AHFS, 2007).  
It is difficult to determine if inhibition of CYP3A by propoxyphene and 
norpropoxyphene has contributed to reported adverse events. Accidental and suicide 
deaths have been attributed to propoxyphene and its metabolite in combination with other 
medications, including benzodiazepines and other analgesics (McBay, 1976). Several 
benzodiazepines (alprazolam, diazepam, midazolam, triazolam) and analgesics (cocaine, 
codeine, fentanyl) are metabolized by CYP3A (Gasche, 2004). Many cases of accidental 
overdoses with propoxyphene have also occurred in combination with other pain 
medication (Gram, 1979) such as opioids (Ng and Alvear, 1993), and many opioids are 
metabolized by CYP3A (Moody, 1996).  
Table 7 (p43) lists predicted increases in drug concentrations for some common 
CYP3A substrates as a result of drug interactions with propoxyphene and 
norpropoxyphene through inhibition of CYP3A enzymes. The AUC'po/AUCpo is a ratio of 
the area under the plasma concentration versus time curve of an orally administered drug 
in the presence of inhibitor (AUC'po) to the AUC without inhibitor present (AUCpo). The 
predicted drug interactions (AUC'po/AUCpo’s) with propoxyphene and norpropoxyphene 
were determined for common CYP3A substrates using Equation 6 (p46). The total blood 
concentrations of propoxyphene and norpropoxyphene (I), were used to calculate the free 
concentrations (Iu) based on 76.5% plasma protein binding (from an average of 73-80% 
plasma protein binding based on Giacomini et al, 1980). The KI and kinact kinetic 
parameters for propoxyphene and norpropoxyphene and human liver microsomes were 
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incorporated into Equation 6. The estimates assume a maximal inhibition of intestinal 
wall CYP3A by propoxyphene and norpropoxyphene (F’G = 1), after repeated dosing. 
The estimates of in vivo drug interactions were calculated for low, moderate, and high 
blood concentrations of propoxyphene and corresponding concentrations of 
norpropoxyphene, for intravenous midazolam only. Subsequent estimates use only the 
median concentrations for propoxyphene and norpropoxyphene. The AUC'po/AUCpo 
values were calculated separately for propoxyphene and norpropoxyphene and then 
added together for net effect (see Table 7, p43), as per Wang et al’s studies with 
verapamil and metabolites (2004).  
The predicted AUC'po/AUCpo values of orally administered midazolam with 
propoxyphene are approximately fifteen to twenty-five times the blood concentrations of 
midazolam administered alone. In general, the lower the intestinal availability of the 
substrate prior to the addition of inhibitor (FG) and the greater the fraction metabolized by 
CYP3A (fm), the greater the predicted change with propoxyphene co-administration. 
Sildenafil, triazolam, and R-verapamil have a predicted blood concentrations (AUC) that 
are at least ten times higher when administered with propoxyphene. Verapamil is a weak 
CYP3A inducer, and actual blood levels may be slightly lower than predicted (Wang, 
2005). All drugs show a predicted increase in AUC by at least four-fold with 
propoxyphene (and norpropoxyphene).  
Although AUC'po /AUC po data were not available for many of the drugs listed in 
Table 7 (p43), some AUC'po/AUCpo values with propoxyphene have been documented. 
Abernethy et al (1985) reported that the AUC'po/AUCpo values for alprazolam was 1.6 
following three 60 mg propoxyphene doses/day for two days. Using Equation 6, the 
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predicted AUC'po/AUCpo for alprazolam in humans with co-administration of 
propoxyphene is seven to ten, which is more than three times the reported ratio. The 
discrepancy between predicted and actual AUC'po/AUCpo for alprazolam may be 
attributed to a lower frequency of propoxyphene administration compared to the dose 
used for calculations in Table 7 (p43)16. Additionally, the discrepancy between the 
predicted and actual AUC'po/AUCpo for alprazolam may be attributed to its low rate of 
metabolism by the intestine (Obach et al, 2006). If the drug is not as affected by 
propoxyphene-mediated intestinal CYP inhibition, the actual intensity of the drug 
interaction may be less than predicted by Equation 6 (AUC'po/AUCpo).  
Equation 6 may be more accurate for midazolam and other CYP3A substrates that 
are metabolized by both the liver and small intestine (Obach et al, 2006). The predicted 
AUC changes for oral midazolam with propoxyphene co-administration are fifteen to 
twenty-five times the AUCpo of midazolam alone. Also, midazolam is not transported by 
P-glycoprotein, a transport pump which could reduce the amounts of drug in the intestine. 
Reducing the amount of drug in the intestine could directly affect the amount of CYP 
inhibited. (Wang et al, 2004). Abernethy et al (1985) also reported that AUC changes 
were not observed for diazepam or lorazepam when co-administered with propoxyphene. 
These benzodiazepines are not CYP3A substrates as is the case for midazolam, triazolam, 
and alprazolam.  
Propoxyphene has reduced the clearance and increased the half-life of other 
CYP3A substrates not included in Table 7 (p43) due to lack of sufficient information for 
                                                 
16 Test subjects taking 65 mg propoxyphene hydrochloride every 6 hours for two and a half-days were 
administered 1.0 mg of alprazolam once (Abernethy, 1985). Table 6 AUC changes are based on a 
plasma concentration of 0.6 µM propoxyphene from administration of 65 mg propoxyphene 
hydrochloride three times a day for four days (Verbeley and Inturrisi, 1973). See Table 5. 
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calculations with Equation 617. Propoxyphene decreased the total metabolic clearance of 
antipyrine from 0.53 to 0.63 mL/min, resulting in an increase in the elimination half-life 
of antipyrine from 12.2 to 15.2 hours (Abernethy, 1982). Abernethy et al (1982) found 
that propoxyphene increased the steady-state plasma levels of doxepin and 
desmethyldoxepin from 19 to 44 ng/mL and 9 to 20 ng/mL, depressing cognitive function 
proportionally.  
A drug-drug interaction can have serious clinical consequences if the difference 
between toxic and effective concentrations is small (Lin and Lu, 1998), which is the case 
for propoxyphene (Inturrisi et al, 1982), see Table 6 (p42). Propoxyphene has been 
associated with many accidental deaths. The high reported rates of accidental overdose 
may be attributed to the irreversible inhibition of CYP3A enzymes by propoxyphene and 
norpropoxyphene. The potential drug-drug interactions of propoxyphene through CYP3A 
inhibition may also have contributed to propoxyphene-related overdoses and adverse 
events. Inhibition of CYP3A enzymes by propoxyphene and norpropoxyphene may result 
in higher concentrations of other CYP3A substrates, resulting in adverse events. 
Proadifen is not available as a drug but could be used as a positive control for 
reversible and irreversible inhibition assays with CYP3A. It has been employed in 
mechanism-based inhibition and metabolic-inhibitor complex formation assays with 
CYP3A and other CYPs (Yamada et al, 1992; Jones et al, 2007). Proadifen is more 
potent than propoxyphene and norpropoxyphene for irreversible inhibition with 
CYP3A4(+b5). It is also a more potent reversible inhibitor than propoxyphene and 
norpropoxyphene with CYP3A4(+b5), CYP3A5(+b5), and human liver microsomes. It is 
                                                 
17 The fraction of the total hepatic elimination due to CYP3A in the absense of inhibitor (fm) and the 
intestinal wall bioavailability of the substrate in the absense of inhibitor (FG) could not be obtained 
from published literature. 
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not a controlled substance like propoxyphene (requiring less paperwork and control for 
laboratory use).  
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CHAPTER 5-CONCLUSION 
Propoxyphene was developed over fifty years ago, before the current knowledge 
of CYP isozymes, metabolism, and CYP-mediated drug-drug interactions. The results of 
these studies show that propoxyphene and norpropoxyphene are irreversible inhibitors of 
CYP3A as measured by in vitro experiments with CYP3A4(+b5), CYP3A5(+b5), and 
human liver microsomes. Propoxyphene and norpropoxyphene exhibit little or no 
reversible inhibition of CYP3A, and are more potent irreversible inhibitors of CYP3A. 
Both propoxyphene and norpropoxyphene form metabolic-inhibitor complexes with 
CYP3A4(+b5) and CYP3A5(+b5). Proadifen, a compound of similar structure to 
propoxyphene and norpropoxyphene, is a potent irreversible inhibitor of CYP3A4. 
Proadifen is also an irreversible inhibitor of CYP3A5 and human liver microsomes, and 
exhibits reversible inhibition with CYP3A4(+b5), CYP3A5(+b5), and human liver 
microsomes.  
   Many reported propoxyphene overdoses may be accidental and attributed to the 
irreversible inhibition of CYP3A enzymes by propoxyphene, which may result in higher 
than predicted blood concentrations of the drug or its metabolite, norpropoxyphene. 
Inhibition of CYP3A enzymes by propoxyphene and norpropoxyphene may result in 
higher concentrations of other CYP3A substrates, resulting in adverse events.  
  Future studies may be conducted to provide additional information regarding 
propoxyphene and norpropoxyphene inhibition of CYP3A. These include testing 
CYP3A4(+b5) and CYP3A5(+b5) for regeneration of activity following propoxyphene 
and norpropoxyphene pre-incubation experiments to determine if the irreversible 
inhibition is completely irreversible. Additionally, propoxyphene and norpropoxyphene 
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may be examined in combination in irreversible inhibition experiments to assess 
cumulative, additive, or synergistic effect. A study may also be conducted to monitor 
concentrations of propoxyphene, norpropoxyphene and dinorpropoxyphene following 
incubation with CYP3A to assess depletion and product formation. Additionally, 
propoxyphene and norproxyphene may be tested for induction of CYP3A enzymes in 
vitro using established cell culture models. Although propoxyphene and 
norpropoxyphene exhibited irreversible inhibition with recombinant CYP3A enzymes, 
the in vivo inhibition may be less than predicted due to CYP3A enzyme induction, which 
could not be assessed with pre-incubation experiments.  
       A study may also be conducted to compare theoretical and actual AUC values of 
patients taking propoxyphene alone and in combination with other CYP3A substrates. As 
a part of this study, patients may be genotyped to determine if any CYP3A 
polymorphisms exist. Providing genotyping information would enhance data 
interpretation, and highlight which sub-populations, if any, are more susceptible to 
propoxyphene mediated CYP3A inhibition and drug-drug interactions. 
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 Table 1. Chemical Structures of Propoxyphene, Methadone, Codeine, Norpropoxyphene 
and Dinorpropoxyphene.  
 
Propoxyphene CH3
O
O
CH3
N CH3
CH2
CH3
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CH3
CH3CH3
O
CH3
 
Codeine 
N
CH3O O OH
CH3
 
Norpropoxyphene CH3
O
O
CH3
N CH3
H
CH2
Dinorpropoxyphene  
(linear) 
CH3
O
O
CH3
N H
H
CH2
 
     
(Feinberg et al,1976; McMahon, 1961; Somogyi et al, 2004) 
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Table 2. Chemical Structures of Proadifen (SKF-525a) and SKF-8742  
Prodifen (SKF-525a) 
O
O
N CH3
CH3
CH3
 
SKF-8742 
O
O
N CH3
H
CH3
 
(Anders and Mannering, 1966) 
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Table 3. List of CYP3A4 and CYP3A5 Common Polymorphisms 
Enzyme Expression of Functional Protein in  
Adult Population 
Major  
Organs  
Alleles Activity Relative to Wild Type 
CYP3A4*1(A) Wildtypef 
CYP3A4*17 Reduced CYP3A4 expressiona 
CYP3A4*18 Increased CYP3A4 expressiona 
CYP3A4 
Majority of population expresses CYP3A4 Liver Small Intestinef
CYP3A4*1B Increased CYP3A4 activity over wildtypeb 
Decreased CYP3A4 expression over wildtypec 
CYP3A5*1(A) Wildtype, 
Dominant Allele, produced functional protein (*1/*3)e 
CYP3A5 1-30% of Caucasians
d 
55-75% of Black Africans and African Americansd
33% of Japanesed 
Kidney 
Lung 
Liver 
Colonf CYP3A5 *2, 
*3, *5, *6, *7 Less than 30% of wild type CYP3A5 protein
e 
aDai et al, 2001; bKuehl et al, 2001; cWojnoski et al, 2002; dKamden et al, 2005; eKreutz et al, 2005; fDanielson, 2002 
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Table 4. Summary of Kinetic Parameters for Enzyme Inactivation (Irreversible Inhibition) with Propoxyphene, 
Norpropoxyphene, and Proadifen 
 
                    
Tissue Inhibitor Kinact (min-1) KI (µM) MIC Formation
Norpropoxyphene 0.56 (+/- 0.07) 8.8 (+/- 2.1) Yes
Proadifen 0.26 (+/- 0.03) 0.35 (+/- 0.16) Yes
Propoxyphene 0.072 (+/- 0.005) 13 (+/- 3.0) Yes
Norpropoxyphene 0.21 (+/-0.03) 25 (+/-8.7) Yes
Proadifen 0.11 (+/-0.01) 20 (+/-4.6) Yes
Propoxyphene 0.038 (+/-0.002) 0.45 (+/-0.13) None detected
Norpropoxyphene 0.074(+/-0.004) 8.2 (+/-1.4) None detected
Proadifen 0.2 (+/-0.04) 6.9 (+/-2.4) Yes
Yes
CYP3A5(+b5)
Human Liver Microsomes
CYP3A4(+b5)
Propoxyphene 0.41 (+/- 0.03) 1.3 (+/- 0.28)
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Table 5. Reversible Inhibition Ki Values  
 
 
Inhibitor Tissue Ki µM (Standard Error) 
CYP3A4(+b5) 26 (+/- 3.0) 
CYP3A5(+b5) >100, estimated 134 (+/-32) Propoxyphene 
Human Liver Microsomes >80, estimated 155 (+/-22) 
CYP3A4(+b5) 29 (+/-5.0) 
CYP3A5(+b5) >100, estimated 186 (+/-24) Norpropoxyphene 
Human Liver Microsomes 59 (+/-0.049) 
CYP3A4(+b5) 5.4 (+/-0.042) 
CYP3A5(+b5) 12 (+/- 1.0) Proadifen 
Human Liver Microsomes 8.3 (+/- 0.61) 
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Table 6. Reported Therapeutic (Total) Blood Levels of Propoxyphene and Norpropoxyphene 
 
Dose Frequency Duration Propoxyphene  (µg/mL) 
Propoxyphene  
(µM) 
Norpropoxyphene 
 (µg/mL) 
Norpropoxyphene  
(µM) 
130 mg Propoxyphene 
hydrochloride a 1 time only once 0.3
a 0.9 0.3 a 0.9 
65 mg Propoxyphene 
hydrochloride a 3 doses/day 4 days 0.1-0.2
a 0.4-0.7 0.6 a 1.8 
130 mg Propoxyphene 
hydrochloride a 3 doses/day 4 days 0.7-0.9
a 2-2.5 1.1-1.2 a 3.4-3.7 
550 mg Propoxyphene 
hydrochloride b 2 dose/Day 12 weeks  0.5
b 1.5 5 b 15 
Toxic levels c n/a n/a >0.5c >1.5 n/a n/a 
Therapeutic  
concentration d n/a n/a ≥ 0.05
d ≥ 0.15 n/a n/a 
 
aVerbeley and Inturrissi, 1973; bInturrisi et al, 1982; c Merck Manual, 2007; dAHFS, 2007 
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Table 7. Predictions of Propoxyphene and Norproxyphene Interactions with Other CYP3A Substrates (AUC'po/AUCpo) 
Propoxyphene Norproxyphene Propoxyphene Norproxyphene Propoxyphene + Norproxyphene 
I (µM) Iu (µM) I (µM) Iu (µM) 
CYP3A 
Substrates fm FG Predicted 
AUC'po/ AUCpo 
Predicted 
AUC'po/ AUCpo 
Predicted 
AUC'po/ AUCpo 
0.6 a 0.1 1.8 a 0.4 Midazolam-iv c 0.9 c 1 d 5-8 3-6 8-14 
2.3a 0.5 3.6 a 0.8 Midazolam-iv c 0.9 c 1 d 7-9 4-8 11-17 
1.5b 0.4 15 b 3.5 Midazolam-iv c 0.9 c 1 d 6-9 6-9 12-18 
0.6 a 0.1 1.8 a 0.4 Midazolam-oral c 0.9 c 0.4 c 8-10 7-15 15-25 
0.6 a 0.1 1.8 a 0.4 Sildenafil e 0.8f 0.4g 8-11 6-10 14-21 
0.6 a 0.1 1.8 a 0.4 Alprazolamo 0.8 l 0.9 l 4-5 3-5 7-10 
0.6a 0.1 1.8 a 0.4 Triazolam k 0.8 l 0.4l 8-10 6-9 14-19 
0.6a 0.1 1.8 a 0.4 Trazodone h 0.4i 0.8 j 2 2 4 
0.6 a 0.1 1.8 a 0.4 R-Verapamilm 0.8m 0.5n 5-6 5-9 10-15 
0.6 a 0.1 1.8 a 0.4 S-Verapamilm 0.7m 0.5n 7-11 7-11 14-22 
 
aVerbeley and Inturrisi, 1973,; bAHFS, 2007; c Palkama et al, 1999; d Ernest et al, 2004; e Muirhead et al; f Warrington et al, 2000; g Thummel and Shen, 2001;h 
Greenblatt et al, 2003;i Jaunch et al, 1976;j Nilson and Dale, 1992; kGreenblatt et al, 2000a;l Rodrigues et al, 2001; m Wang et al, 2004; n Gorski et al, 1998; 
oGreenblatt et al, 2000b 
 
The predicted AUC'po/AUCpo values were determined for propoxyphene and norpropoxyphene separately using Equation 6, and then added together. The total 
blood concentrations of propoxyphene and norpropoxyphene (I), were used to calculate the free concentrations (Iu) based on 76.5% plasma protein binding 
(Giacomini et al, 1978). The fraction of total hepatic elimination of substrate due to CYP3A in the absence of inhibitor is fm, and was obtained from the scientific 
literature. FG is the intestinal wall bioavailability of the substrate in the absence of inhibitor. The endogenous degradation rate of CYP3A (kdeg) were 0.00128 and 
0.00026 min-1 based on rat CYP3A and human CYP3A4 in CaCO-2 cells (Correa, 1991; Malhotra et al, 2001).  
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Schematic I. Irreversible Inhibition 
 
 
 
 
 
 
(Silverman, 1995) 
 
 
 
Schematic II. Irreversible Inhibition: Formation of Proposed Metabolic-Inhibitor 
Complex 
 
 
 
 
 
 
(Bensoussan et al, 1995) 
In this schematic, dialkylamine group of the inhibitor is demethylated twice, oxidized, 
and finally forms a nitroso group (R-N=O). The two free electrons of the nitrogen in the 
nitroso group binds to the iron of the heme of the prosthetic group of the CYP. 
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Schematic III. Reversible Inhibition. Enzyme (E) Binds Substrate (S) or Inhibitor (I).  
 
E+S ES E+P
+
I
EI
k1
k-1
k2
Ki
    (Stryer, 1996) 
The k1, k-1, and k2 rates are listed but are not calculated as part of this thesis. 
  
 45
Equation 1. Irreversible Inhibition Equation for Enzyme Activity (at time (t)), Enzyme 
Activity at Time (0), and Kobserved (Kobs) at Time (t) 
 
 
 
 
Equation 2a. Irreversible Inhibition Equation for kobserved (kobs), kinact, and KI. 
 
 
 
 
 
Equation 2b. Irreversible Inhibition Equation for kobserved, kinact, and KI and Enzyme 
Activity 
 
 
 
Equation 3. Competitive Inhibition Equation 
 
Y= (Vmax x S)/((Km x (1+I/ Ki )+S) 
 
 
Equation 4. Noncompetitive Inhibition Equation 
Y= ((Vmax /(1+I/ Ki ))+S)/(Km +S) 
 
 
Equation 5. Uncompetitive Inhibition Equation 
 
Y= (Vmax x S) /( Km +(S(1+I/ Ki))) 
 
Equation 6. Calculating AUC'po/AUCpo using kinetic parameters 
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Figure 1. HPLC Chromatogram of Extracted Sample After Incubation with Recombinant CYP. Mobile Phase: 40% 30 mM 
ammonium acetate pH 6.3-6.4: 60% methanol . HPLC conditions: 5 µm C-18(2) Luna Phenomenex column with a 1 ml/min flow rate 
and uv detection at 254 nm. 
6β hydroxy testosterone  
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Testosterone 
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Figure 2. HPLC Chromatogram of Extracted Sample After Incubation with Human Liver Microsomes. Mobile Phase: 40% 30 mM 
ammonium acetate pH 5.6-5.8: 60% methanol . HPLC conditions: 5 µm C-18(2) Luna Phenomenex column with a 1 ml/min flow rate 
and uv detection at 254 nm.  
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Figure 3. Propoxyphene and CYP3A4(+b5)-Percent Activity v. Pre-incubation Time. Time and concentration dependent inhibition of 
CYP3A4(+b5) activity by propoxyphene. For each concentration of inhibitor, the remaining testosterone 6β hydroxylase activity is 
expressed as a percentage relative to control activity. Points are averaged data, and lines are generated from Equation 2b (p46) with 
kinact and KI model estimates. 
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Figure 4. Propoxyphene and CYP3A5(+b5)-Percent Activity v. Pre-incubation Time. Time and concentration dependent inhibition of 
CYP3A5(+b5) activity by propoxyphene. For each concentration of inhibitor, the remaining testosterone 6β hydroxylase activity is 
expressed as a percentage relative to control activity. Points are averaged data, and lines are generated from Equation 2b (p46) with 
kinact and KI model estimates. 
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Figure 5. Propoxyphene and Human Liver Microsomes-Percent Activity v. Pre-incubation Time. Time and concentration dependent 
inhibition of CYP3A activity in human liver microsomes by propoxyphene. For each concentration of inhibitor, the remaining 
testosterone 6β hydroxylase activity is expressed as a percentage relative to control activity. Points are averaged data, and lines are 
generated from Equation 2b (p46) with kinact and KI model estimates. 
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Figure 6. Norpropoxyphene and CYP3A4(+b5)-Percent Activity v. Pre-incubation Time. Time and concentration dependent 
inhibition of CYP3A4(+b5) activity by propoxyphene. For each concentration of inhibitor, the remaining testosterone 6β hydroxylase 
activity is expressed as a percentage relative to control activity. Points are averaged data, and lines are generated from Equation 2b 
(p46) with kinact and KI model estimates. 
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Figure 7. Norpropoxyphene and CYP3A5(+b5)-Percent Activity v. Pre-incubation Time. Time and concentration dependent 
inhibition of CYP3A5(+b5) activity by propoxyphene. For each concentration of inhibitor, the remaining testosterone 6β hydroxylase 
activity is expressed as a percentage relative to control activity. Points are averaged data, and lines are generated from Equation 2b 
(p46) with kinact and KI model estimates. 
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Figure 8. Norpropoxyphene and human liver microsomes-Percent Activity v. Pre-incubation Time. Time and concentration dependent 
inhibition of CYP3A activity in human liver microsomes by propoxyphene. For each concentration of inhibitor, the remaining 
testosterone 6β hydroxylase activity is expressed as a percentage relative to control activity. Points are averaged data, and lines are 
generated from Equation 2b (p46) with kinact and KI model estimates. 
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Figure 9. Proadifen and CYP3A4(+b5)-Percent Activity v. Pre-incubation Time. Time and concentration dependent inhibition of 
CYP3A4(+b5) activity by propoxyphene. For each concentration of inhibitor, the remaining testosterone 6β hydroxylase activity is 
expressed as a percentage relative to control activity. Points are averaged data, and lines are generated from Equation 2b (p46) with 
kinact and KI model estimates. 
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Figure 10. Proadifen and CYP3A5(+b5)-Percent Activity v. Pre-incubation Time. Time and concentration dependent inhibition of 
CYP3A5(+b5) activity by propoxyphene. For each concentration of inhibitor, the remaining testosterone 6β hydroxylase activity is 
expressed as a percentage relative to control activity. Points are averaged data, and lines are generated from Equation 2b (p46) with 
kinact and KI model estimates. 
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Figure 11. Proadifen and Human Liver Microsomes-Percent Activity v. Pre-incubation Time. Time and concentration dependent 
inhibition of CYP3A activity in human liver microsomes by propoxyphene. For each concentration of inhibitor, the remaining 
testosterone 6β hydroxylase activity is expressed as a percentage relative to control activity. Points are averaged data, and lines are 
generated from Equation 2b (p46) with kinact and KI model estimates. 
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Figure 12. kobs v. Inhibitor Concentration for CYP3A4(+b5) and Propoxyphene. The kobs values were calculated using the slopes of 
the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) and the KI 
and kinact model estimates.  
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Figure 13. kobs v. Inhibitor Concentration for CYP3A5(+b5) and Propoxyphene. The kobs values were calculated using the slopes of 
the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) and the KI 
and kinact model estimates. 
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Figure 14. kobs v. Inhibitor Concentration for Human Liver Microsomes and Propoxyphene. The kobs values were calculated using the 
slopes of the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) 
and the KI and kinact model estimates.  
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Figure 15. kobs v. Inhibitor Concentration for CYP3A4(+b5) and Norpropoxyphene. The kobs values were calculated using the slopes 
of the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) and the 
KI and kinact model estimates.  
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Figure 16. kobs v. Inhibitor Concentration for CYP3A5(+b5) and Norpropoxyphene. The kobs values were calculated using the slopes 
of the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) and the 
KI and kinact model estimates. 
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Figure 17. kobs v. Inhibitor Concentration for Human Liver Microsomes and Norpropoxyphene. The kobs values were calculated using 
the slopes of the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using equation 2a (p46) 
and the KI and kinact model estimates.  
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Figure 18. kobs v. Inhibitor Concentration for CYP3A4(+b5) and Proadifen. The kobs values were calculated using the slopes of the 
lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) and the KI and 
kinact model estimates. 
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Figure 19. kobs v. Inhibitor Concentration for CYP3A5(+b5) and Proadifen. The kobs values were calculated using the slopes of the 
lines of best fit from percent activity versus pre-incubation time data. The Kobs line was calculated using Equation 2a (p46) and the KI 
and kinact model estimates. 
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Figure 20. kobs v. Inhibitor Concentration for Human Liver Microsomes and Proadifen. The kobs values were calculated using the 
slopes of the lines of best fit from percent activity versus pre-incubation time data. The line was calculated using Equation 2a (p46) 
and the KI and kinact model estimates.  
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Figure 21. Propoxyphene and CYP3A4(+b5)-Percent Activity Relative to Control. The percentage of initial testosterone 6β 
hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no 
inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 
mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of 
replicates. 
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Figure 22. Propoxyphene and CYP3A5(+b5)-Percent Activity Relative to Control. The percentage of initial testosterone 6β 
hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no 
inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 
mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of 
replicates. 
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Figure 23. Propoxyphene and Human Liver Microsomes-Percent Activity Relative to Control. The percentage of initial testosterone 
6β hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no 
inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 
mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of 
replicates. 
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Figure 24. Norpropoxyphene and CYP3A4(+b5)-Percent Activity Relative to Control. The percentage of initial testosterone 6β 
hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no 
inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 
mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of 
replicates. 
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Figure 25. Norpropoxyphene and CYP3A5(+b5)-Percent Activity Relative to Control. The percentage of initial testosterone 6β 
hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no 
inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 
mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of 
replicates. 
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Figure 26. Norpropoxyphene and Human Liver Microsomes-Percent Activity Relative to Control. The percentage of initial 
testosterone 6β hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined 
relative to the no inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor 
concentration (1 mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard 
deviations of replicates. 
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Figure 27. Proadifen and CYP3A4(+b5)-Percent Activity Relative to Control. The percentage of initial testosterone 6β hydroxylase 
activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no inhibitor zero 
pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 mL reaction) and 
pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of replicates. 
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Figure 28. Proadifen and CYP3A5(+b5)-Percent Activity Relative to Control. The percentage of initial testosterone 6β hydroxylase 
activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no inhibitor zero 
pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 mL reaction) and 
pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of replicates. 
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Figure 29. Proadifen and Human Liver Microsomes-Percent Activity Relative to Control. The percentage of initial testosterone 6β 
hydroxylase activity for each inhibitor concentration without pre-incubation time (time 0) activity was determined relative to the no 
inhibitor zero pre-incubation time (0,0 control). Concentrations of inhibitor are listed across the x-axis as inhibitor concentration (1 
mL reaction) and pre-incubation concentrations are listed in parentheses (50 µL reaction). Error bars are standard deviations of 
replicates. 
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Figure 30. Metabolic-Inhibitor Complex Formation by Propoxyphene with CYP3A4(+b5). Metabolic-inhibitor complex formation was 
detected by a uv spectrophotometer by calculating the absorbance difference between the experimental cuvette and reference cuvette. 
Both contained CYP3A4(+b5), phosphate buffer, NADPH, and methanol, but only to a reference cuvette contained propoxyphene. 
Absorbance was measured scanning wavelengths of 400-500 nm over 30 minutes. 
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   APPENDIX-SUMMARY OF STATISTICAL METHODS 
AIC     The Akaike Information Criteria determines the goodness of fit for models with  
different parameters (Akaike, 1987). For comparing multiple models with the  
same variables (such as competitive, noncompetitive, and uncompetitive modes),  
the smallest AIC is the best fit.  
 
AIC = Nobservations x log (WRSS) + 2 (NParameters) 
CV The coefficient of variation is calculated by taking the standard deviation divided 
by the mean and expressed as a percentage. It is a way of comparing the degree of 
variation of one series to another, even if the means are different from one 
another. 
 
 CV = (SD/Mean) x 100 
Mean Arithmatic average 
SBC    The Schwartz Bayesian Criterion measures goodness of fit based on maximum 
likelihood. For comparing models with similar (or no) weighting, the model with 
the smallest SBC value is the best fit.  
 
SBC = Nobservations x log (WRSS) + Log(Nobservations) x NParameters 
 
SD The standard deviation of the mean, it is a measure of dispersion of a data set 
from its mean. It is calculated as the square root of the sum (Σ) of all differences 
from the mean (xi − µ), etc. squared, divided by the number of observations 
minus one (n-1). It is equal to the square root of the variance. (Σ  square root 
(xi − µ))2/n-1) 
 
SE  The standard error of the mean, calculated by the dividing the standard deviation        
            by the square root of the sample size (n).  
 
   SE = SD/(√N) 
WRSS Weighted residual sum of squares, estimates the variance of the residuals.   
            (Residuals are observed minus predicted values, and predicted values come from  
            model fitting). It is the sum of squared deviations from the mean where the  
            means are the predicted parameter values.  
 
                                                                                        (Pharsight Windows Nonlin 5.0.1) 
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